Enliven Therapeutics, Inc. (Nasdaq: ELVN) announced on October 14, 2026, that it has appointed Kristine Ball to its Board of Directors. The appointment increases the size of the Board from seven to eight directors. Ms. Ball will serve as a Class II director with a term expiring at the Company’s 2028 annual meeting of stockholders. She has also been appointed to the Board’s Audit Committee.
Ms. Ball brings more than 20 years of executive experience in the biopharmaceutical industry. Her background includes serving as Chief Executive Officer of Antiva Biosciences and Soteria Biotherapeutics, as well as Senior Vice President of Corporate Strategy and Chief Financial Officer of Menlo Therapeutics and Relypsa. The Company stated that her experience in helping companies transition from clinical development to commercial operations will be valuable as Enliven prepares for late-stage development.
Enliven is focused on the discovery and development of small molecule therapeutics. The Company noted that it plans to initiate the pivotal Phase 3 trial of relcobatinib (ELVN-001) in patients with previously treated chronic myeloid leukemia (CML) before year-end 2026. This trial is referred to as ENABLE-2. The Company previously announced FDA alignment on the final design of this trial.
Ms. Ball will receive compensation for her service pursuant to the Company’s Outside Director Compensation Policy. This includes an annual cash compensation of $45,000 for service as an outside director and an additional $10,000 per year for service on the Audit Committee. Additionally, as a new outside director, she was granted stock options to purchase shares of the Company’s common stock. The grant date fair value of these options was approximately $650,000. The options will vest as to 1/36th of the total number of shares on each monthly anniversary of the grant date, subject to her continued service. In the event of a Change in Control, the options will vest in full.
Enliven is a clinical-stage biopharmaceutical company based in Burlingame, California. The Company aims to address unmet medical needs with a precision medicine approach.
